Limits...
GTPase regulator associated with the focal adhesion kinase (GRAF) transcript was down-regulated in patients with myeloid malignancies.

Qian Z, Qian J, Lin J, Yao DM, Chen Q, Ji RB, Li Y, Xiao GF, Li JY - J. Exp. Clin. Cancer Res. (2010)

Bottom Line: GTPase regulator associated with the focal adhesion kinase (GRAF), a putative tumor suppressor gene, is found inactivated in hematopoietic malignancies by either genetic or epigenetic abnormalities.As CML progressed, GRAF transcript significantly decreased.In MDS, three cases with 5q deletion had lower GRAF transcript than four without 5q deletion (median 0.76 vs 2.99) (P > 0.05). our results demonstrate that the GRAF transcript is decreased in myeloid malignancies.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Hematology, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu 212002, China. qianjun0007@hotmail.com

ABSTRACT

Background: GTPase regulator associated with the focal adhesion kinase (GRAF), a putative tumor suppressor gene, is found inactivated in hematopoietic malignancies by either genetic or epigenetic abnormalities. However, the expression level of GRAF gene has not yet been studied in leukemia. The aim of this study was to investigate the expression level of GRAF gene in those patients with myeloid malignancies including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and chronic myeloid leukemia (CML).

Methods: The expression levels of GRAF transcript were determined in 94 patients using real-time quantitative PCR (RQ-PCR). Clinical and laboratory data of these patients were collected and analyzed.

Results: The significantly decreased level of GRAF transcript was observed in three myeloid malignancies compared to controls. Within AML, there was no difference in the level of GRAF transcript among different FAB subtypes (P > 0.05). Difference was not observed in the amount of GRAF mRNA between CML at chronic phase and controls. As CML progressed, GRAF transcript significantly decreased. In MDS, three cases with 5q deletion had lower GRAF transcript than four without 5q deletion (median 0.76 vs 2.99) (P > 0.05).

Conclusion: our results demonstrate that the GRAF transcript is decreased in myeloid malignancies.

Show MeSH

Related in: MedlinePlus

Scatterplot showing varying levels of GRAF transcript in patients with different myeloid malignancies and controls.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2927506&req=5

Figure 1: Scatterplot showing varying levels of GRAF transcript in patients with different myeloid malignancies and controls.

Mentions: The level of GRAF transcript in controls was 14.49-126.85 (median 56.04). The significantly decreased level of GRAF transcript was observed in different myeloid malignancies (Table 1, Figure 1). There was no correlation between GRAF mRNA amount and the sex, age, peripheral white blood cell count, hemoglobin level, and platelet count (P > 0.05). The association of GRAF levels with cytogenetic abnormalities or CD34 antigen expression was also not observed in AML patients (P > 0.05). Within AML, there was no difference in the level of GRAF transcript among different FAB subtypes (P > 0.05).


GTPase regulator associated with the focal adhesion kinase (GRAF) transcript was down-regulated in patients with myeloid malignancies.

Qian Z, Qian J, Lin J, Yao DM, Chen Q, Ji RB, Li Y, Xiao GF, Li JY - J. Exp. Clin. Cancer Res. (2010)

Scatterplot showing varying levels of GRAF transcript in patients with different myeloid malignancies and controls.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2927506&req=5

Figure 1: Scatterplot showing varying levels of GRAF transcript in patients with different myeloid malignancies and controls.
Mentions: The level of GRAF transcript in controls was 14.49-126.85 (median 56.04). The significantly decreased level of GRAF transcript was observed in different myeloid malignancies (Table 1, Figure 1). There was no correlation between GRAF mRNA amount and the sex, age, peripheral white blood cell count, hemoglobin level, and platelet count (P > 0.05). The association of GRAF levels with cytogenetic abnormalities or CD34 antigen expression was also not observed in AML patients (P > 0.05). Within AML, there was no difference in the level of GRAF transcript among different FAB subtypes (P > 0.05).

Bottom Line: GTPase regulator associated with the focal adhesion kinase (GRAF), a putative tumor suppressor gene, is found inactivated in hematopoietic malignancies by either genetic or epigenetic abnormalities.As CML progressed, GRAF transcript significantly decreased.In MDS, three cases with 5q deletion had lower GRAF transcript than four without 5q deletion (median 0.76 vs 2.99) (P > 0.05). our results demonstrate that the GRAF transcript is decreased in myeloid malignancies.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Hematology, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu 212002, China. qianjun0007@hotmail.com

ABSTRACT

Background: GTPase regulator associated with the focal adhesion kinase (GRAF), a putative tumor suppressor gene, is found inactivated in hematopoietic malignancies by either genetic or epigenetic abnormalities. However, the expression level of GRAF gene has not yet been studied in leukemia. The aim of this study was to investigate the expression level of GRAF gene in those patients with myeloid malignancies including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and chronic myeloid leukemia (CML).

Methods: The expression levels of GRAF transcript were determined in 94 patients using real-time quantitative PCR (RQ-PCR). Clinical and laboratory data of these patients were collected and analyzed.

Results: The significantly decreased level of GRAF transcript was observed in three myeloid malignancies compared to controls. Within AML, there was no difference in the level of GRAF transcript among different FAB subtypes (P > 0.05). Difference was not observed in the amount of GRAF mRNA between CML at chronic phase and controls. As CML progressed, GRAF transcript significantly decreased. In MDS, three cases with 5q deletion had lower GRAF transcript than four without 5q deletion (median 0.76 vs 2.99) (P > 0.05).

Conclusion: our results demonstrate that the GRAF transcript is decreased in myeloid malignancies.

Show MeSH
Related in: MedlinePlus